Lexicon Pharmaceuticals (LXRX) Competitors

Dynavax Technologies (NASDAQ:DVAX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Do insiders and institutionals have more ownership in DVAX or LXRX?

97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by company insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media prefer DVAX or LXRX?

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Dynavax Technologies. MarketBeat recorded 4 mentions for Lexicon Pharmaceuticals and 2 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.77 beat Lexicon Pharmaceuticals' score of -0.20 indicating that Dynavax Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dynavax Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is DVAX or LXRX more profitable?

Dynavax Technologies has a net margin of -20.39% compared to Lexicon Pharmaceuticals' net margin of -568.04%. Dynavax Technologies' return on equity of 3.59% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynavax Technologies	-20.39%	3.59%	2.20%
Lexicon Pharmaceuticals	-568.04%	-103.16%	-54.95%

Which has stronger valuation and earnings, DVAX or LXRX?

Dynavax Technologies has higher revenue and earnings than Lexicon Pharmaceuticals. Dynavax Technologies is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynavax Technologies	$277.25M	4.64	$27.31M	-$0.52	-20.62
Lexicon Pharmaceuticals	$31.08M	14.31	-$200.40M	-$0.51	-2.41

Do analysts rate DVAX or LXRX?

Dynavax Technologies currently has a consensus price target of $24.00, suggesting a potential upside of 123.88%. Lexicon Pharmaceuticals has a consensus price target of $3.67, suggesting a potential upside of 198.10%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Dynavax Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynavax Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lexicon Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Which has more risk & volatility, DVAX or LXRX?

Dynavax Technologies has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Summary

Dynavax Technologies beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.